HDL3
lipoproteinHDL3 participates in reverse cholesterol transport with diminished antiplatelet capacity compared to HDL2.
Pathway placement
Cascade stepLipid retention & oxidation
Confidencemedium
RationaleHDL subclass with reduced antiplatelet potency; lipid transport.
Also acts inPlatelet activation
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I43
C — confounder / Type-II46
A — assay feasibility82
E — evidence strength20
T1DI (composite)8
Specificity differential (R−C)-3.4
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Specialized reference method
Specimen
Serum or plasma (EDTA)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
NMR lipoprotein particle analysis or density-gradient ultracentrifugation
Reagent / substrate
No chemical reagent — NMR spectral deconvolution of lipid methyl signals (or ultracentrifugal separation by density)
Platform
NMR (LabCorp NMR LipoProfile) / analytical ultracentrifuge
Turnaround · availability
Send-out · Specialized reference lab
Literature evidence(1)
- Acute coronary syndrome remodels the antiplatelet aggregation properties of HDL particle subclasses.Journal of thrombosis and haemostasis : JTH · 2018 · PMID 29543379 · doi